IDT Australia Ltd
ASX:IDT
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
IDT Australia Ltd
ASX:IDT
|
19.8m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
IDT Australia Ltd
Glance View
IDT Australia Ltd. produces, develops and supplies pharmaceutical products. The company is headquartered in Melbourne, Victoria. The firm is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. The firm specializes in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging and pharmacy services. The company provides services for new drug development and scale-up, commercial active drug manufacture as well as a various oral and injectable finished drug dose forms. Its sterile manufacturing suite is designed to liquid fill and lyophilise a range of sterile pharmaceutical and biopharmaceutical drug products. Its current goods manufacturing practices (cGMP) facilities manufactures a range of medicinal cannabis products for local and international markets.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for IDT Australia Ltd is -40.6%, which is above its 3-year median of -57.7%.
Over the last 3 years, IDT Australia Ltd’s Net Margin has decreased from -9.6% to -40.6%. During this period, it reached a low of -136.4% on Dec 31, 2022 and a high of -9.6% on Jun 30, 2022.
